Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 15, 2026, ANDA 211506 (Dapagliflozin), held by Macleods Pharms, was first approved by FDA on Apr 6, 2026, with 0 approved supplements and 0 published complete response letters.
First approved: Apr 6, 2026
Review: Standard
Supplements approved: 0
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Dapagliflozin is indicated:
To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use
Dapagliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
Dapagliflozin is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2. Dapagliflozin is likely to be ineffective in this setting based upon its mechanism of action.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters